Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
- PMID: 20505526
- PMCID: PMC2978283
- DOI: 10.1097/MCG.0b013e3181dd1348
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
Abstract
Goals and background: The recently developed histologic scoring system for nonalcoholic fatty liver disease (NAFLD) by the nonalcoholic steatohepatitis (NASH) Clinical Research Network (CRN) is becoming increasingly popular. However, its generalizability to a community setting has not been evaluated. We conducted a study to compare a community general pathologist to an expert hepatopathologist in assessing NAFLD using the NASH CRN scoring system.
Study: Forty-eight consecutive patients with suspected NAFLD underwent liver biopsy. Histologic features of interest such as steatosis, lobular inflammation, balloon degeneration, fibrosis, NAFLD Activity Score (NAS), and the presence of NASH were scored in a blinded fashion by the 2 pathologists on 2 separate occasions 3 months apart.
Results: The mean (± SD) length of the liver biopsy samples was 25 ± 5 mm. Interobserver agreement (κ) between 2 pathologists was 0.62 (0.45-0.80) for steatosis, 0.44 (0.23-0.65) for lobular inflammation, 0.25 (0.11-0.38) for ballooning, 0.40 for NAS (0.28-0.52), and 0.35 (0.19-0.52) for fibrosis. The 2 pathologists diagnosed "definite NASH" in a similar proportion of patients (56% vs. 57%), but their interobserver agreement was only 0.46 (0.24-0.67) as they both diagnosed different levels of NASH (borderline vs. definite) in different subjects. Intraobserver agreement was generally comparable for steatosis, lobular inflammation, NAS, and diagnosis of NASH, but not for fibrosis.
Conclusions: Clinically important differences exist between community general pathologist and expert hepatopathologist in assessing NAFLD using the NASH CRN scoring system. More studies are needed to investigate its suitability for community-based clinical practice.
Figures


Similar articles
-
High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.Clin Gastroenterol Hepatol. 2020 Aug;18(9):2081-2090.e9. doi: 10.1016/j.cgh.2019.12.025. Epub 2019 Dec 27. Clin Gastroenterol Hepatol. 2020. PMID: 31887451 Free PMC article.
-
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742. APMIS. 2017. PMID: 29076589
-
Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology. 2005 Jun;41(6):1313-21. doi: 10.1002/hep.20701. Hepatology. 2005. PMID: 15915461
-
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539. World J Gastroenterol. 2014. PMID: 25400438 Free PMC article. Review.
-
[Role of liver biopsy in the diagnosis of NASH].Nihon Rinsho. 2006 Jun;64(6):1119-25. Nihon Rinsho. 2006. PMID: 16768119 Review. Japanese.
Cited by
-
An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials.Diagnostics (Basel). 2020 Aug 28;10(9):643. doi: 10.3390/diagnostics10090643. Diagnostics (Basel). 2020. PMID: 32872090 Free PMC article.
-
Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years.Eur J Pediatr. 2020 May;179(5):719-726. doi: 10.1007/s00431-019-03551-0. Epub 2020 Jan 2. Eur J Pediatr. 2020. PMID: 31897838
-
Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review.J Clin Med. 2021 Dec 7;10(24):5721. doi: 10.3390/jcm10245721. J Clin Med. 2021. PMID: 34945016 Free PMC article. Review.
-
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.Drugs. 2015 Aug;75(12):1373-92. doi: 10.1007/s40265-015-0437-3. Drugs. 2015. PMID: 26201461 Free PMC article. Review.
-
Hepatic Fat Quantification with the Multi-Material Decomposition Algorithm by Using Low-Dose Non-Contrast Material-Enhanced Dual-Energy Computed Tomography in a Prospectively Enrolled Cohort.Medicina (Kaunas). 2022 Oct 15;58(10):1459. doi: 10.3390/medicina58101459. Medicina (Kaunas). 2022. PMID: 36295617 Free PMC article.
References
-
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7. - PubMed
-
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95. - PubMed
-
- Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005;329:111–6. - PubMed
-
- Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23. - PubMed
-
- Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous